Greg Moeck, PhD

Senior Vice President, Microbiology
Venatorx Pharmaceuticals

Disclosure: Venatorx Pharmaceuticals (Employee, Shareholder)

Greg Moeck, PhD, Senior Vice President, Clinical Microbiology, Venatorx Pharmaceuticals oversees microbiology development for clinical stage investigational antibacterial agents including cefepime-taniborbactam and ceftibuten-ledaborbactam. He has spent 20 years in antibacterial discovery and development, focusing on identifying, characterizing, and completing clinincal development of antibacterial agents with substantial potential benefit to patients with serious infections due to pathogens that are resistant to currently available treatments.

Poster(s):

1263 - Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM)